Years after it was OK'd, AMAG's drug for preventing preterm births fails badly in long-awaited confirmatory trial

Years after it was OK'd, AMAG's drug for preventing preterm births fails badly in long-awaited confirmatory trial

Source: 
Endpoints
snippet: 

Eight years after the FDA offered its controversial OK for a drug dubbed Makena to prevent preterm births, the drugmaker who now controls it says the confirmatory study — begun a decade ago — is finally complete.